Keros Therapeutics, Inc. (NASDAQ:KROS) Shares Sold by D. E. Shaw & Co. Inc.

D. E. Shaw & Co. Inc. decreased its position in shares of Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) by 93.5% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 12,099 shares of the company's stock after selling 174,189 shares during the quarter. D. E. Shaw & Co. Inc.'s holdings in Keros Therapeutics were worth $192,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also recently modified their holdings of the company. AlphaQuest LLC raised its holdings in Keros Therapeutics by 469.0% in the 4th quarter. AlphaQuest LLC now owns 3,596 shares of the company's stock valued at $57,000 after buying an additional 2,964 shares during the period. Virtus ETF Advisers LLC raised its holdings in Keros Therapeutics by 107.5% in the 4th quarter. Virtus ETF Advisers LLC now owns 3,857 shares of the company's stock valued at $61,000 after buying an additional 1,998 shares during the period. KLP Kapitalforvaltning AS purchased a new stake in Keros Therapeutics in the 4th quarter valued at about $90,000. Exchange Traded Concepts LLC purchased a new stake in Keros Therapeutics in the 4th quarter valued at about $99,000. Finally, CANADA LIFE ASSURANCE Co raised its holdings in Keros Therapeutics by 207.8% in the 4th quarter. CANADA LIFE ASSURANCE Co now owns 7,371 shares of the company's stock valued at $116,000 after buying an additional 4,976 shares during the period. Institutional investors and hedge funds own 71.56% of the company's stock.

Keros Therapeutics Price Performance

Shares of KROS stock traded up $0.51 during trading hours on Monday, reaching $14.66. 507,460 shares of the stock were exchanged, compared to its average volume of 846,398. The business's fifty day moving average is $13.07 and its two-hundred day moving average is $18.85. Keros Therapeutics, Inc. has a 12-month low of $9.12 and a 12-month high of $72.37. The firm has a market capitalization of $595.42 million, a P/E ratio of -2.81 and a beta of 1.32.

Keros Therapeutics (NASDAQ:KROS - Get Free Report) last released its earnings results on Tuesday, May 6th. The company reported $3.62 earnings per share for the quarter, topping analysts' consensus estimates of ($0.01) by $3.63. Keros Therapeutics had a negative net margin of 27,890.94% and a negative return on equity of 41.74%. The firm had revenue of $211.25 million for the quarter, compared to analyst estimates of $84.62 million. During the same period in the prior year, the firm earned ($1.21) earnings per share. As a group, equities research analysts predict that Keros Therapeutics, Inc. will post -4.74 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on KROS shares. Truist Financial reduced their price objective on shares of Keros Therapeutics from $43.00 to $25.00 and set a "buy" rating on the stock in a report on Wednesday, April 9th. Scotiabank cut their price target on shares of Keros Therapeutics from $41.00 to $26.00 and set a "sector outperform" rating on the stock in a research note on Monday, May 12th. HC Wainwright cut their price target on shares of Keros Therapeutics from $40.00 to $25.00 and set a "buy" rating on the stock in a research note on Thursday, May 8th. Wells Fargo & Company cut their price target on shares of Keros Therapeutics from $28.00 to $26.00 and set an "overweight" rating on the stock in a research note on Thursday, February 27th. Finally, Wedbush reiterated a "neutral" rating and set a $15.00 price target on shares of Keros Therapeutics in a research note on Friday. Six analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $37.00.

Insider Activity at Keros Therapeutics

In other Keros Therapeutics news, major shareholder Adar1 Capital Management, Llc purchased 934,258 shares of the stock in a transaction that occurred on Wednesday, April 9th. The stock was purchased at an average cost of $10.13 per share, with a total value of $9,464,033.54. Following the completion of the acquisition, the insider now directly owns 4,392,737 shares of the company's stock, valued at $44,498,425.81. This trade represents a 27.01% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 20.60% of the stock is currently owned by corporate insiders.

Keros Therapeutics Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.